Clearbridge Investments LLC Acquires 46,036 Shares of OR Royalties Inc. $OR

Clearbridge Investments LLC grew its holdings in shares of OR Royalties Inc. (NYSE:OR) by 30.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 199,039 shares of the basic materials company’s stock after buying an additional 46,036 shares during the quarter. Clearbridge Investments LLC’s holdings in OR Royalties were worth $7,044,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of OR. Assetmark Inc. bought a new stake in shares of OR Royalties in the 4th quarter valued at about $36,000. Caitlin John LLC acquired a new position in OR Royalties in the 3rd quarter valued at about $78,000. Allworth Financial LP grew its stake in OR Royalties by 20.0% in the 4th quarter. Allworth Financial LP now owns 2,305 shares of the basic materials company’s stock valued at $82,000 after buying an additional 384 shares during the last quarter. Merit Financial Group LLC acquired a new position in OR Royalties in the 3rd quarter valued at about $215,000. Finally, Flow Traders U.S. LLC acquired a new position in OR Royalties in the 3rd quarter valued at about $217,000. 68.52% of the stock is owned by institutional investors.

OR Royalties Stock Down 4.9%

Shares of NYSE OR opened at $31.41 on Thursday. The company has a market capitalization of $5.89 billion, a PE ratio of 23.44 and a beta of 0.70. OR Royalties Inc. has a twelve month low of $24.76 and a twelve month high of $48.06. The firm has a fifty day simple moving average of $37.90 and a 200 day simple moving average of $38.74.

OR Royalties (NYSE:OR) last released its earnings results on Wednesday, May 6th. The basic materials company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%.The business had revenue of $102.83 million during the quarter, compared to analysts’ expectations of $103.27 million. As a group, equities analysts expect that OR Royalties Inc. will post 1.4 earnings per share for the current fiscal year.

OR Royalties Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.065 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This is a boost from OR Royalties’s previous quarterly dividend of $0.06. This represents a $0.26 annualized dividend and a dividend yield of 0.8%. OR Royalties’s payout ratio is presently 18.66%.

Wall Street Analysts Forecast Growth

OR has been the topic of a number of research reports. Wall Street Zen lowered shares of OR Royalties from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $56.00 price target on shares of OR Royalties in a research note on Friday, April 10th. TD Securities restated a “hold” rating on shares of OR Royalties in a research report on Monday, February 23rd. Weiss Ratings lowered shares of OR Royalties from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 4th. Finally, Zacks Research lowered shares of OR Royalties from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, OR Royalties presently has an average rating of “Moderate Buy” and an average target price of $46.50.

OR Royalties Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.